20-Dec-2024
Sarepta awarded $115.2M in Vyondys 53 patent case: report
Seeking Alpha News (Fri, 20-Dec 6:00 PM ET)
Mizuho Securities Reaffirms Their Buy Rating on Sarepta Therapeutics (SRPT)
TipRanks (Fri, 20-Dec 12:50 PM ET)
TipRanks (Fri, 20-Dec 12:26 PM ET)
25 U.S. ‘highest conviction’ stocks – UBS
Seeking Alpha News (Thu, 19-Dec 10:48 AM ET)
Business Wire (Wed, 18-Dec 8:30 AM ET)
Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Business Wire (Fri, 29-Nov 4:10 PM ET)
Business Wire (Tue, 26-Nov 7:00 AM ET)
Business Wire (Tue, 26-Nov 7:00 AM ET)
Business Wire (Wed, 6-Nov 4:05 PM ET)
Sarepta Therapeutics to Announce Third Quarter 2024 Financial Results
Business Wire (Wed, 23-Oct 8:30 AM ET)
Sarepta Therapeutics Inc is a biotechnology company focused on treating rare, infectious, and other diseases. It targets a broad range of diseases while focusing on the rapid development of its drug candidates. Sarepta's strategy involves proprietary RNA-targeted technology platforms to be used for developing novel pharmaceutical products to treat a broad range of diseases and address key unmet medical needs. The company uses third-party contractors to manufacture its product candidates. Most of company's product candidates are at an early stage of development.
Sarepta Therapeutics trades on the NASDAQ stock market under the symbol SRPT.
As of December 20, 2024, SRPT stock price declined to $118.97 with 1,318,094 million shares trading.
SRPT has a beta of 1.50, meaning it tends to be more sensitive to market movements. SRPT has a correlation of 0.14 to the broad based SPY ETF.
SRPT has a market cap of $11.36 billion. This is considered a Large Cap stock.
Last quarter Sarepta Therapeutics reported $467 million in Revenue and $.62 earnings per share. This beat revenue expectation by $58 million and exceeded earnings estimates by $.25.
In the last 3 years, SRPT traded as high as $173.25 and as low as $55.25.
The top ETF exchange traded funds that SRPT belongs to (by Net Assets): IJH, VTI, VB, VXF, XBI.
SRPT has outperformed the market in the last year with a return of +31.8%, while the SPY ETF gained +27.8%. However, in the most recent history, SRPT shares have underperformed the stock market with its stock returning -6.5% in the last 3 month period and -7.2% for the last 2 week period, while SPY has returned +4.4% and -2.4%, respectively.
SRPT support price is $116.37 and resistance is $122.58 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that SRPT shares will trade within this expected range on the day.